Skip to content

Pulmonary Embolism WArsaw REgistry

Pulmonary Embolism WArsaw REgistry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03916302
Acronym
PE-aWARE
Enrollment
1500
Registered
2019-04-16
Start date
2008-01-01
Completion date
2028-12-31
Last updated
2023-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pulmonary Embolism

Keywords

acute pulmonary embolism

Brief summary

Initiated in January 2008, The PE-aWARE (Pulmonary Embolism WArsaw REgistry) is an on-going single-centre prospective observational study of patients with confirmed acute pulmonary embolism (APE). Extensive data on consecutive patients with pulmonary embolism is collected and stored. The main objective is to collect and provide information on patients' characteristics, management, and outcome with the purpose of decreasing mortality in APE, the occurrence of bleeding, and the frequency of thromboembolic recurrences. Moreover, the PE-aWARE registry serves as a basis for creating predictive scores for clinicians which aid patient management. The study endpoints comprise clinically recognized (and objectively confirmed) recurrences of PE, major and minor bleeding complications classified according to the International Society on Thrombosis and Haemostasis classification, need for cardiopulmonary resuscitation or catecholamines, and death.

Detailed description

The Pulmonary Embolism WArsaw REgistry (PE-aWARE) is an on-going prospective observational study of patients with confirmed acute pulmonary embolism (APE). Carried out since January 2008, the registry includes consecutive patients hospitalized at a single centre. The primary data recorded include details of each patient's clinical status, co-morbidities, the prescribed treatment, the results of additional studies (ie EKG, imaging studies), and the outcome. The study endpoints comprise clinically recognized (and objectively confirmed) recurrences of PE, major and minor bleeding complications classified according to the International Society on Thrombosis and Haemostasis classification, need for cardiopulmonary resuscitation or catecholamines, and death. Collecting the fore mentioned data allows for clinicians to better manage the diagnostic workup and treatment and thus facilitates the prevention of possible future complications in APE patients.

Interventions

None listed

Sponsors

Medical University of Warsaw
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* objectively confirmed pulmonary embolism * Informed consent for the participation in the study, according to the requirements of the ethics committee

Exclusion criteria

* lack of consent

Design outcomes

Primary

MeasureTime frameDescription
Composite primary outcomein-hospital (average of 10 days)at least one of the following: 1. systolic blood pressure \< 90 mmHg for at least 15 minutes 2. need for catecholamine administration because of persistant arterial hypotension or shock 3. need for mechanical ventilation 4. need for cardiopulmonary resuscitation

Secondary

MeasureTime frameDescription
Major or non-major clinically relevant bleeding defined according to the International Society on Thrombosis and Haemostasisin-hospital (average of 10 days)Secondary outcome measure

Other

MeasureTime frameDescription
5-year follow-up5 yearsPatients will be evaluated annually at least during first 5 years after index PE for VTE recurrence and for Post PE syndrome (PPS) including chronic thromboembolic pulmonary hypertension (CTEPH), chronic thromboembolic pulmonary disease (CTEPD), newly diagnosed neoplasms, cardiovascular diseases (coronary artery disease, stroke, heart failure) and functional limitation resulting from psychological sequel of acute PE.

Countries

Poland

Contacts

Primary ContactPiotr Pruszczyk, Prof.
piotr.pruszczyk@wum.edu.pl00 48 22 502 11 44
Backup ContactMarta Z Skowronska, MD
marta.z.kozlowska@gmail.com00 48 22 502 16 25

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026